Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children

Antiviral Therapy

Volumn 14, Issue 4, 2009, Pages 603-606

  La Porte, Charles ^a   van Heeswijk, Rolf ^a,b   Mitchell, Charles D ^c   Zhang, Guijun ^a   Parker, Jackie ^d   Rongkavilit, Chokechai ^d  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b TIBOTEC BVBA   (Belgium)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ADOLESCENT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; DRUG ADMINISTRATION; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PYRIMIDINONES; RITONAVIR;

EID: 68549117137     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Kaletra® (lopinavir/ritonavir). Product monograph 2007. Abbott Laboratories Ltd., North Chicago, IL, USA; pp. 1-27.
2. van der Lee M, Verweel G, de Groot R, Burger D. Pharmacokinetics of a once-dail regimen of lopinavir/ritonavir in HIV-1 infected children. Antivir Ther 2006; 11:439-445.
3. Rosso R, Di Biagio A, Dentone C, et al. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. J Antimicrob Chemother 1006; 57:1168-1171.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. November 3, 2008 (Updated 3 November 2008. Accessed 15 February 2009.) Available from www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
5. Chadwick EG, Capparelli EV, Yogev R, et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS 2008; 22:249-255.
6. Verweel G, Burger DM, Sheehan NL, et al. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below. Antivir Ther 2007; 12:453-458.
7. Boffito M, Else I, Back D, et al. Pharmacokinetics of atazanavir/ ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antivir Ther 2008; 13:901-907.
8. Kaletra lower-strength pediatric tablet approved in Europe. AIDS Patient Care STDS 2008; 22:437-438.
9. van der Flier M, Verweel G, van der Knaap LC, et al. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily. Antivir Ther 2008; 13:1087-1090.